tci Part B Insider - 2004 Issue 3

Drug Coding: CMS Throws Practices a Curve Ball With J0880 Reversal

You have two choices of codes for non-ESRD Aranesp claimsThe Centers for Medicare & Medicaid Services flip-flopped on an important new drug code, and the result is confusion for coders. First CMS said that J0880 Injection, darbepoetin alfa, 5 mcg) wouldn't be payable by Medicare after Jan. 1, 2004. Then in late December, CMS changed its tune and said J0880 would remain payable, but only for claims in the physician office.  Complicating matters, CMS recognizes two Q codes for darbepoetin alfa, otherwise known as Aranesp. For patients with ESRD receiving Aranesp, you should use new code Q4054...

To read the full article, sign in and subscribe to tci Part B Insider.


Keep pace with evolving Medicare regulations with timely analysis of critical updates interpreted in an easy-to-follow, easy-to-apply format. Your subscription to TCI’s Part B Insider will equip you to navigate code and guideline changes, CCI edits, and revisions to modifiers, the fee schedule, OIG target areas, and more.

  • Current newsletters added each month
  • Fully searchable archives - over 4800 articles
  • ALL years/issues back to 2003 organized by year and issue
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information pages link back to related articles
Access to this feature is available in the following products:
  • tci Part B Insider +Archives

free demo
request yours today
pricing
for any budget
sign IN
welcome back!